Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria.

ABSTRACT:

Background

The 8-aminoquinoline antimalarials, the only drugs which prevent relapse of vivax and ovale malaria (radical cure), cause dose-dependent oxidant haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients with <30% and <70% of normal G6PD activity are not given standard regimens of primaquine and tafenoquine, respectively. Both drugs are currently considered contraindicated in pregnant and lactating women.

Methods

Quantitative G6PD enzyme activity data from 5198 individuals were used to estimate the proportions of heterozygous females who would be ineligible for treatment at the 30% and 70% activity thresholds, and the relationship with the severity of the deficiency. This was used to construct a simple model relating allele freque

SUBMITTER: Watson J 

PROVIDER: S-EPMC5931686 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature